Novo Nordisk, a Danish multinational pharmaceutical company and a global leader in diabetes care, has launched its new generation insulin in Oman.

Tresiba is a once-daily basal insulin for people with diabetes that successfully achieves equivalent reductions in blood glucose levels, with a lower risk of nocturnal hypoglycemia versus insulin glargine1,2.

The new product also allows for flexibility in day-to-day dosing time, when needed without compromising efficacy or risk of hypoglycemia3-5, said the Danish company in a statement.

One of the key challenges with insulin therapy is the risk of hypoglycemia, when blood glucose levels fall to lower than normal levels, causing unpleasant symptoms, such as dizziness and confusion, unconsciousness and sometimes leads to death6,7.

Research shows that fears and concerns about hypoglycemia can interfere with achieving optimal glycaemic control in people with diabetes using insulin8.

Hypoglycemia that occurs at night is of particular concern9 for people living with diabetes, as it is unpredictable and difficult to detect10.
    
Results from studies over a two-year period show the new insulin therapy successfully achieves equivalent reductions in HbA1c, but with a lower risk of nocturnal hypoglycemia compared to insulin glargine:

•43 per cent for people with type 2 diabetes1
•25 per cent for people with type 1 diabetes2

Dr Mohammed Lamki, the consultant endocrinologist at The Royal Hospital – Oman, said: "The new insulin therapy can be administered at any time of the day, offering flexible dosing when needed. This flexibility could help improve the lives of patients, as poor insulin adherence contributes to poor glycemic control."

Complications from diabetes caused by failing to keep optimal glycaemic control can be serious, and may include problems such as heart disease, stroke, blindness, kidney disease, nerve damage and premature mortality11,12, he explained.

In Oman, nearly 326,000 people live with diabetes, whhile 35.8 per cent of those with diabetes are still undiagnosed.

"Maintaining good blood glucose control with insulin treatment can be challenging for healthcare professionals and patients due to concerns over hypoglycaemia and night- time hypoglycaemia in particular," stated Vikrant Shrotriya, VP Gulf, Novo Nordisk..

"Tresiba has shown less risk of nocturnal hypoglycaemia than the most widely used basal insulin," he added.-TradeArabia News Service